Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

J. von Pawel, R. Bordoni, M. Satouchi, L. Fehrenbacher, M. Cobo, J. Y. Han, T. Hida, D. Moro-Sibilot, P. Conkling, David R Gandara, A. Rittmeyer, M. Gandhi, W. Yu, C. Matheny, H. Patel, A. Sandler, M. Ballinger, M. Kowanetz, K. Park

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Fingerprint Dive into the research topics of 'Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study'. Together they form a unique fingerprint.

Medicine & Life Sciences